Glaxosmithkline plc, of London, and Innoviva Inc., of South San Francisco, reported top-line results from the pivotal phase III FULFIL study of once-daily, triple-combination therapy (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) comprising an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist, in patients with chronic obstructive pulmonary disease.